Post-Hemorrhagic Anemia Treatment Market - Top Companies and Manufacturers

Companies Dominating the Post-Hemorrhagic Anemia Treatment Landscape

Rockwell Medical, Inc.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
Amgen Inc.
Vifor Pharma Management Ltd.
F. Hoffmann-La Roche Ltd
Pfizer Inc.
Novartis AG
Teva Pharmaceutical Industries Ltd.
Johnson & Johnson Services, Inc.
AMAG Pharmaceuticals
Akebia Therapeutics

Pfizer Inc. announced the acquisition of Global Blood Therapeutics, Inc., a leading developer and provider of treatments for SCD patients. With this acquisition, Pfizer aims to advance these treatments in the rare hematology space of sickle cell diseases.
F. Hoffmann-La-Roche Ltd. Announced the approval of the European Commission for the expansion of Hemlibra. With this expansion, Roche aims to include bleeding episodes in hemophilia A patients without the use of factor VII inhibitors